Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
Public ClinicalTrials.gov record NCT00474786. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an international, randomized, open-label, outpatient, multicenter study. Subjects will be assigned in a 1:1 ratio to 1 of 2 treatment arms: temsirolimus 25 mg once weekly by intravenous (IV) infusion or sorafenib 400 mg by mouth (PO) twice daily (BID). These investigational drugs will be administered in 6-week cycles for the duration of the study, up to 24 months. Subjects will be stratified by nephrectomy status, duration of response to sunitinib therapy, Memorial Sloan Kettering Cancer Center (MSKCC) prognostic group, and RCC tumor histology.
Study identification
- NCT ID
- NCT00474786
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 512 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2007
- Primary completion
- Dec 31, 2011
- Completion
- Dec 31, 2012
- Last update posted
- Nov 20, 2013
2007 – 2013
United States locations
- U.S. sites
- 26
- U.S. states
- 13
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Duarte | California | 91010 | — |
| Pfizer Investigational Site | La Jolla | California | 92037 | — |
| Pfizer Investigational Site | La Jolla | California | 92093 | — |
| Pfizer Investigational Site | Los Angeles | California | 90095-6984 | — |
| Pfizer Investigational Site | Los Angeles | California | 90095 | — |
| Pfizer Investigational Site | Orange | California | 92868 | — |
| Pfizer Investigational Site | Riverside | California | 92505 | — |
| Pfizer Investigational Site | San Diego | California | 92103 | — |
| Pfizer Investigational Site | Meriden | Connecticut | 06451 | — |
| Pfizer Investigational Site | Municie | Indiana | 47303 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40202 | — |
| Pfizer Investigational Site | Metairie | Louisiana | 70006 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21201 | — |
| Pfizer Investigational Site | Bethesda | Maryland | 20817 | — |
| Pfizer Investigational Site | Tupelo | Mississippi | 38801 | — |
| Pfizer Investigational Site | New York | New York | 10065 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44195 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73120 | — |
| Pfizer Investigational Site | Tulsa | Oklahoma | 74104 | — |
| Pfizer Investigational Site | Austin | Texas | 78731 | — |
| Pfizer Investigational Site | Dallas | Texas | 75226 | — |
| Pfizer Investigational Site | Dallas | Texas | 75246 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | Salt Lake City | Utah | 84112-5550 | — |
| Pfizer Investigational Site | Salt Lake City | Utah | 84412 | — |
| Pfizer Investigational Site | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 102 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00474786, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 20, 2013 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00474786 live on ClinicalTrials.gov.